Core Viewpoint - SoFi Technologies, Inc. (NASDAQ:SOFI) is considered a promising stock by analysts, despite recent price target adjustments reflecting market conditions and analyst sentiment [1][2][3]. Analyst Ratings - Truist Financial analyst Matthew Coad reaffirmed a Hold rating on SoFi, lowering the price target from $28 to $21, indicating an 18.2% upside potential from current levels [1]. - Citizens JMP analyst Devin Ryan upgraded SoFi from Market Perform to Outperform, maintaining a price target of $30, which suggests a 66% upside from current levels after a 35% year-to-date decline [2]. Market Sentiment - The recent decline in SoFi's stock is attributed to a broader market shift away from high-growth stocks, driven by technical factors rather than immediate economic concerns. This situation is viewed as a buying opportunity by some analysts [3]. Company Overview - SoFi Technologies operates as a financial services provider in multiple regions, including Canada, the United States, Hong Kong, and Latin America. The company has various segments, including Technology Platform, Lending, and Financial Services, offering products like the SoFi Credit Card and SoFi Relay [4].

Morgan Stanley is cutting about 3% of its workforce https://t.co/uFItc69LUR ...

Core Viewpoint - A class-action lawsuit has been filed against Cushman & Wakefield U.S. Inc. for allegedly breaching its fiduciary duties under ERISA by failing to protect employees' 401(k) savings from climate-related financial risks, which could lead to significant changes in risk management across the $12 trillion U.S. retirement market [1][6]. Group 1: Allegations Against Cushman & Wakefield - The lawsuit claims that Cushman & Wakefield did not adequately evaluate, monitor, or remove the Westwood Quality SmallCap Fund, which poses high climate-related financial risks and has underperformed while charging excessive fees [2][3]. - The Westwood Quality SmallCap Fund reportedly disclaims climate risk analysis and lagged behind benchmarks by 17% in 2025, while its fees were significantly higher than those of comparable funds [3]. - There is an alleged inconsistency between Cushman & Wakefield's corporate risk management practices and its management of employee retirement funds, as the company recognizes climate change as a financial risk but did not apply similar analysis to its 401(k) plan [4]. Group 2: Implications of the Lawsuit - The lawsuit could set a legal precedent that mandates climate risk management as part of fiduciary duty, potentially impacting the management of the $12 trillion in retirement savings held in 401(k)-style plans [6]. - The case signals to the financial industry that fiduciaries must acknowledge climate change as an economic reality and cannot ignore it without facing potential liability [6]. Group 3: Statements from Plaintiffs and Legal Experts - The lead plaintiff expressed disappointment over the exposure of retirement savings to climate-related risks, emphasizing the expectation that employers ensure the soundness of retirement options [7]. - Legal experts highlighted that climate risk is a significant economic risk, and failing to address it undermines the fiduciary responsibility of financial managers [8].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Lufax Holding Ltd due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Investors who purchased Lufax securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Lufax [2]. Group 2: Company Background and Recent Developments - On January 27, 2025, Lufax filed a current report with the SEC indicating a proposal to remove its auditors and a potential delay in the publication of its 2024 annual report, which subsequently led to a 13.8% drop in Lufax's American Depositary Shares [3]. - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Cohen & Company Inc. will announce its financial results for Q4 and the full year ended December 31, 2025, on March 6, 2026, followed by a conference call to discuss these results [1]. Group 1: Financial Results Announcement - The financial results will be released on March 6, 2026 [1]. - A conference call is scheduled for 10:00 a.m. Eastern Time on the same day to discuss the results [1]. Group 2: Conference Call Details - The conference call will be available via webcast on the company's homepage [2]. - For those wishing to listen with operator assistance, domestic and international dial-in numbers are provided [2]. - A replay of the call will be available for three days post-call with specific dial-in details and a participant passcode [2]. Group 3: Company Overview - Cohen & Company specializes in capital markets and asset management services, with segments including Capital Markets, Asset Management, and Principal Investing [3]. - As of December 31, 2025, the company managed approximately $1.4 billion in assets, primarily in fixed income assets across various classes [3]. - The Capital Markets segment includes a full-service boutique investment bank providing advisory services and investment returns on financial instruments [3].

Core Viewpoint - MidCap Financial Investment (MFIC) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For MidCap Financial, the recent increase in earnings estimates suggests an improvement in the company's underlying business, likely leading to upward pressure on its stock price [5][8]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade of MidCap Financial to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions - For the fiscal year ending December 2026, MidCap Financial is expected to earn $1.43 per share, with a 0.7% increase in the Zacks Consensus Estimate over the past three months [8].

Market Overview - The Cosby index experienced a significant decline of approximately 19% over two trading days, marking its worst performance in history [1] - The sell-off is attributed to multiple factors, including the conflict in Iran, which impacts energy imports, and profit-taking after a substantial market run-up [2][3] Energy Market Impact - South Korea's heavy reliance on LNG imports is a critical factor in its market performance, compounded by a stronger dollar and a depreciating South Korean won [3] - The ongoing conflict's duration will significantly influence energy supply disruptions, with potential implications for memory chip shortages and energy prices [4][10] Investment Sentiment - Despite the recent pullback, the market remains up 21% year-to-date, indicating underlying strength [7][8] - Retail investors have been net buyers during the recent sell-off, suggesting a potential opportunity for those capitalizing on the market dip [13] U.S. Market Dynamics - The U.S. market is somewhat insulated due to its own natural gas and crude oil holdings, but the global impact of the conflict is evident, particularly with a 50% spike in natural gas prices in Europe [9] - The U.S. equity markets are currently testing key support levels, with a focus on maintaining the December lows and the 100-day moving average [18][19] Geopolitical Considerations - The Strait of Hormuz is a critical area to monitor, as current oil traffic is halted, raising concerns about future supply and pricing [15][17] - The U.S. government's proposed risk insurance for tanker escorts may not be sufficient to resume oil traffic, highlighting the complexities of the geopolitical situation [16]

Group 1 - Voya presents an attractive investment opportunity due to its complementary businesses that operate at scale and hold a leadership position in workplace businesses [1] - The collection of Voya's businesses generates high return on equity and high free cash flow, enabling continued investment in operations and meaningful capital returns to shareholders [1] Group 2 - Voya's business mix serves customers at every life stage, from new employees enrolling in retirement plans to those enjoying retirement savings [2] - The retirement business is central to Voya's operations in the workplace, complemented by asset management and employee benefit offerings that help secure customers' financial futures [2]

Group 1: BrightSpring Health Services, Inc. (BTSG) - BrightSpring Health Services is a parent company providing home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care [1] - The company has a Zacks Rank of 1 (Strong Buy) and its current year earnings estimate has increased by 10% over the last 60 days [1] - BrightSpring Health Services' shares gained 15.7% over the last three months, outperforming the S&P 500, which declined by 0.7% [2] Group 2: XP (XP) - XP is a technology-driven financial services platform offering financial products and services primarily in Brazil [2] - The company holds a Zacks Rank of 1 and has seen a 4.7% increase in its current year earnings estimate over the last 60 days [2] - XP's shares increased by 3.2% over the last three months, also outperforming the S&P 500's decline of 0.7% [3] Group 3: Catalyst Pharmaceuticals (CPRX) - Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare and difficult-to-treat diseases [3] - The company has a Zacks Rank of 1 and its current year earnings estimate has risen by 2% over the last 60 days [3] - Catalyst Pharmaceuticals' shares rose by 3.6% over the last three months, again outperforming the S&P 500's decline of 0.7% [4]

🇺🇸 SEN. LUMMINS: “We are creating the 21st century financial services industry”, as Kraken gains direct access to the US payment system. https://t.co/1lbc4Y1HKz ...